

Resource Summary Report

Generated by [dkNET](#) on Sep 2, 2026

Chk1 (2G1D5) Mouse mAb

RRID:AB_2080320

Type: Antibody

Proper Citation

Cell Signaling Technology Cat# 2360, RRID:AB_2080320

Antibody Information

URL: http://antibodyregistry.org/AB_2080320

Proper Citation: Cell Signaling Technology Cat# 2360, RRID:AB_2080320

Target Antigen: Chk1

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: W. Consolidation on 10/2018: AB_10694643, AB_2080320.

Antibody Name: Chk1 (2G1D5) Mouse mAb

Description: This monoclonal targets Chk1

Target Organism: rat, mouse, human

Clone ID: Clone 2G1D5

Antibody ID: AB_2080320

Vendor: Cell Signaling Technology

Catalog Number: 2360

Record Creation Time: 20250819T235140+0000

Record Last Update: 20250820T063846+0000

Ratings and Alerts

No rating or validation information has been found for Chk1 (2G1D5) Mouse mAb.

No alerts have been found for Chk1 (2G1D5) Mouse mAb.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 86 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Wang Q, et al. (2026) FANCA-dependent FEN1 recruitment suppresses transcription-replication conflicts and PARPi sensitivity. *Molecular cell*.

Dutta Chowdhury D, et al. (2026) TNIK overexpression is sufficient for chemoradiation resistance in limited-stage small cell lung cancer. *Molecular cancer therapeutics*.

Dommer AP, et al. (2026) Cyclin E modulates vulnerability to CDC7 kinase inhibition. *Oncogenesis*, 15(1).

Wang D, et al. (2026) PRMT5 is Frequently Upregulated and a Potential Therapeutic Target in MTAP-deficient Malignant Peripheral Nerve Sheath Tumors. *bioRxiv : the preprint server for biology*.

Planas-Paz L, et al. (2026) Targeting ATR signaling in sarcoma with homologous recombination deficiency. *Cancer letters*, 642, 218300.

Tian M, et al. (2026) Targeted antibody-drug conjugates for rhabdomyosarcoma and other FGFR4-expressing cancers. *Cell reports. Medicine*, 7(7), 102922.

Gu JJ, et al. (2026) ABL kinase inactivation induces transcription-replication conflicts and impairs replication fork progression in metastatic small cell lung cancer. *Cell reports*, 45(7), 117699.

Chatterjee S, et al. (2026) Pathogenesis of Noonan Syndrome is Modulated by NOC2L, a Novel Interactor of LZTR1 Leading to Impaired P53 Signalling. *The Journal of clinical endocrinology and metabolism*, 111(5), 1418.

Xu G, et al. (2026) Delactylation of the tumor suppressor ARHGDIB drives metastasis and chemoresistance in bladder cancer. *Cell reports*, 45(2), 116941.

Ma Y, et al. (2026) Exploiting the polypharmacology of alectinib for synergistic RNA splicing disruption with RBM39 degraders. *Cell reports*, 45(1), 116784.

Ialchina R, et al. (2026) Microenvironmental acidosis drives PARP- and ATM inhibitor resistance in p53 deficient pancreatic cancer. *iScience*, 29(3), 115112.

Aussel A, et al. (2026) Tumor metabolic adaptation induced by L-asparaginase reveals a vulnerability to PARP1/2 inhibitor in B-cell lymphomas. *Nature communications*, 17(1).

Schnabel JL, et al. (2025) IMPDH inhibition induces DNA replication stress and ATR sensitivity in Merkel cell carcinoma. *iScience*, 28(6), 112567.

Lemay SE, et al. (2025) Unraveling AURKB as a potential therapeutic target in pulmonary hypertension using integrated transcriptomic analysis and pre-clinical studies. *Cell reports. Medicine*, 6(2), 101964.

Xue F, et al. (2025) CRISPR/Cas9 Screening Highlights PFKFB3 Gene as a Major Contributor to 5-Fluorouracil Resistance in Esophageal Cancer. *Cancers*, 17(10).

Zhu X, et al. (2025) Circular RNA circATM binds PARP1 to suppress Wnt/??-catenin signaling and induce cell cycle arrest in gastric cancer cells. *Journal of advanced research*.

Cao G, et al. (2025) Interaction and Reciprocal Stabilization of H3.3 and PARP1 Promote DNA Damage Repair and Tumor Progression in Small Cell Lung Cancer. *Cancer research*, 85(24), 4918.

Rivadeneira DB, et al. (2025) Oxidative-stress-induced telomere instability drives T cell dysfunction in cancer. *Immunity*.

Haas A, et al. (2025) Wnt10b signaling regulates replication stress-induced chromosomal instability in human cancer. *Life science alliance*, 8(11).

Ziener J, et al. (2025) Combined inhibition of ribonucleotide reductase and WEE1 induces synergistic anticancer activity in Ewing's sarcoma cells. *BMC cancer*, 25(1), 277.